Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 6 of 6 for “"Ceritinib"”.
-
Off-Target Based Drug Repurposing Using Systems Pharmacology
… the anaplastic lymphoma kinase (ALK) inhibitor, ceritinib, had activity across several ALK-negative lung cancer cell lines. We utilized integrated functional proteomics to identify the new targets and network-wide signaling effects. Combining pharmacological inhibitors and RNA interference …
-
Modelling RANBP2-ALK-rearranged Epithelioid Inflammatory Myofibroblastic Sarcoma
… sensitive to ALK inhibition with crizotinib or ceritinib in vivo. However, this was not reflected by in vitro assays. Therefore, in vivo studies were used for the remainder of the project to validate novel therapeutic strategies identified in vitro. The CD30-targeted agent, brentuximab vedotin …
-
Brigatinib overview: A next generation ALK inhibitor for advance ALK positive NSCLC
… με ALK-θετικό NSCLC είναι το crizotinib, το ceritinib και το alectinib. Το brigatinib θεωρείται ένα πολλά υποσχόμενο φάρμακο καθώς παρουσιάζει δραστικότητα όταν άλλοι ALK αναστολείς είναι αναποτελεσματικοί. Η δράση του brigatinib στηρίζεται στην αναστολή της πρόσδεσης της φωσφορικής ομάδας …
-
THE EFFECT OF RK-33, A NOVEL INHIBITOR OF RNA HELICASE DDX3, ON INFLAMMATORY BREAST CANCER CELLS
… other small molecule inhibitors, Linsitinib and Ceritinib, to observe a potential additive or synergistic relationship. All drug pairings and the drug triad were tested on two IBC cell lines. The scope of this study was limited to suggestions of additivity or synergy, as observed through leftward …
-
Systematic review of ALK inhibitors for metastatic non-small cell lung cancer
… συνιστά τη χρήση των ALK αναστολέων Crizotinib, Ceritinib, Alectinib, Brigatinib και Lorlatinib. Η συλλογή και ανάλυση επιστημονικών κλινικών στοιχείων είναι απαραίτητη για τη χρήση αυτών των νέων θεραπευτικών μεθόδων για τη βελτίωση της ογκολογικής υγειονομικής περίθαλψης. Επιπλέον, η διείσδυση …
-
Mechanistic insights into ALK inhibitor resistance in neuroblastoma
… associated with resistance to the ALK inhibitors ceritinib and lorlatinib. The hypothesis, whether a loss of NF1 can confer ALKi resistance in ALK-mutated neuroblastoma was investigated by generating isogenic NF1 knockout (KO) models using the CRISPR/Cas9 system in respective neuroblastoma cell …